Patents Issued in November 24, 2020
  • Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
    Patent number: 10842770
    Abstract: Non-aqueous taxane pro-emulsion formulations are provided. Pro-emulsion formulations of embodiments of the invention include a taxane, an oil component, a surfactant component and, optionally, a non-aqueous solvent component. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: November 24, 2020
    Assignee: Teikoku Pharma USA, Inc.
    Inventor: Kiichiro Nabeta
  • Composition of docetaxel liposomal injection with high drug loading
    Patent number: 10842771
    Abstract: The present invention relates to a pharmaceutical liposomal composition comprising of about 0.8% w/w to about 1% w/w of docetaxel, about 30% w/w to about 38% w/w of Soya Phosphatidyl Choline, about 0.2% w/w to about 0.8% w/w of Sodium Cholesteryl Sulfate, about 61% w/w to about 68% w/w of Sucrose and a pH adjusting agent, wherein the pH of liposomal composition is less than 3.5 and the process for preparation thereof.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: November 24, 2020
    Assignee: SHILPA MEDICARE LIMITED
    Inventors: Kiran K Jadhav, Prashanth S, Shivakumar Pradeep, Sreenivasa Reddy
  • Cannabis-based bioactive formulations and methods for use thereof
    Patent number: 10842772
    Abstract: Disclosed are compositions and methods for mitigating a tolerance effect from ingestion of cannabis-based medicines in human subjects, for example, subjects having an increased risk of unresponsiveness to one or more therapeutic agents such as, for example, antidepressants and antianxiety drugs. In some methods, the human subjects have been previously treated with one or more therapeutic agents such as, for example, antidepressants, and antianxiety drugs, and have developed at least partial tolerance to the one or more therapeutic agents.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: November 24, 2020
    Inventor: Louis Michael Segreti
  • Water soluble compositions comprising purified cannabinoids
    Patent number: 10842773
    Abstract: This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: November 24, 2020
    Assignee: Canopy Growth Corporation
    Inventor: Kurt Aron Levy
  • Inhibited expression of PD-L1 and enhanced expression of PD-1
    Patent number: 10842774
    Abstract: Processes for treating an autoimmune disease or condition by decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of cinnamtannin D-1 and/or cinnamtannin B-1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in the subject by the step of administering at the desired concentration or for the desired time wherein the composition may increase or decrease the relative expression levels of the genes or proteins while simultaneously ameliorating, preventing, or modulating a cardiac event in the subject.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: November 24, 2020
    Assignee: IN Ingredients, Inc.
    Inventors: Augustin T. Romero, Bolin Qin
  • Methods of treating Prader-Willi syndrome
    Patent number: 10842775
    Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: November 24, 2020
    Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, LEVO THERAPEUTICS, INC.
    Inventors: Lisa Cole Burnett, Dieter Egli, Rudolph L. Leibel, Sara Cotter
  • Hycanthone derivatives and Primaquine derivatives for use in the prevention and/or the treatment of disorders associated to gammaherpesvirus
    Patent number: 10842776
    Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to gammaherpesvirinae, in particular to the human herpesvirus 8 (HHV8) or the human herpes virus 4 (HHV4), and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: November 24, 2020
    Assignees: Assistance Publique—Hopitaua de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Sorbonne Unicersite, Universite Paris Descartes, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Nicolas Dupin, Anne-Geneviève Marcelin, Vincent Calvez, Philippe Grange
  • Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
    Patent number: 10842777
    Abstract: Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: November 24, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Isabella A. Graef, Mamoun M. Alhamadsheh
  • Use and composition for treating myasthenia gravis and other myasthenic syndromes
    Patent number: 10842778
    Abstract: The present invention describes the use of a 5HT3-antagonist, in combination with pyridostigmine, to facilitate the symptomatic treatment of mammalian subjects, and particularly humans, dogs, and cats, suffering from a myasthenic syndrome, notably myasthenia gravis, by providing a therapeutically effective pyridostigmine bromide daily dose without the typical adverse effects.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: November 24, 2020
    Assignee: DAS-MG, INC.
    Inventor: Kathleen E. Clarence-Smith
  • Heterocyclic compounds and their use in preventing or treating bacterial infections
    Patent number: 10842779
    Abstract: The present invention relates to heterocyclic compounds, their process of preparation, pharmaceutical compositions comprising these compounds and use thereof, optionally in combination with other antibacterial agents and/or beta-lactam compounds, for the prevention or treatment of bacterial infections. The present invention also relates to the use of these compounds as ?-lactamase inhibitors and/or as antibacterial agents.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: November 24, 2020
    Assignee: MUTABILIS
    Inventors: Julie Brias, Sophie Chasset, Francis Chevreuil, Nicolas Lecointe, Benoit Ledoussal, Frédéric Le Strat, Julien Barbion
  • Pharmaceutical composition for modified release
    Patent number: 10842780
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: November 24, 2020
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yuuki Takaishi, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Soichiro Nakamura, Kazuhiro Sako
  • Storage stable composition comprising rifaximin alpha
    Patent number: 10842782
    Abstract: The present invention relates to a pharmaceutical composition containing a stable polymorph of rifaximin and a wicking agent as well as a method of preparing the same.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: November 24, 2020
    Assignee: Sandoz AG
    Inventors: Franz Xaver Schwarz, Arthur Pichler
  • Avibactam and carbapenems antibacterial agents
    Patent number: 10842783
    Abstract: Described are methods of treating or preventing a bacterial infection by administering an antibacterial agent comprising a ?-lactamase inhibitor and one or more carbapenem to a subject.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: November 24, 2020
    Assignee: The Johns Hopkins University
    Inventor: Gyanu Lamichhane
  • Treatment of energy utilization disease
    Patent number: 10842784
    Abstract: Described are compositions comprising imino sugar acids for the treatment of energy utilization disease (e.g. metabolic syndrome, including any disease or disorder associated therewith, for example central obesity, elevated levels of triglycerides and diabetes, including type 1 diabetes, type 2 diabetes and insulin resistance), processes for producing said compositions from various plant sources, together with various products, compounds, compositions, medical uses and methods based thereon.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: November 24, 2020
    Assignee: Vida Pharma Limited
    Inventors: Robert James Nash, Francis Xavier Wilson, Graeme Horne
  • PIM kinase inhibitors in combination with RNA splicing modulators/inhibitors for treatment of cancers
    Patent number: 10842785
    Abstract: The present invention provides for a method of treating cancer and/or reducing proliferation of cancer cells, the method comprising administering to a subject in need of such treatment a composition comprising a PIM kinase inhibitor that exhibits changes of mRNA splicing in combination with a compound that modulates/inhibits activity of an RNA splicing factor protein. Further, changes in splicing of mRNAs and phosphorylation of RNA splicing factors can be used as biomarkers for patient responsiveness to anti-PIM treatment and also suggest effective combinatorial therapies, including synergistic combination.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: November 24, 2020
    Assignee: THE UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventors: Charles J. Bieberich, Xiang Li, Tejashree Joglekar
  • Chewing gum composition comprising cannabinoids and nicotine
    Patent number: 10842786
    Abstract: A chewing gum composition comprising cannabinoids or derivatives thereof and nicotine in the form of nicotine polacrilex is provided. The chewing gum composition is formulated to provide rapid and controlled release of cannabinoids and nicotine during chewing. Methods to provide tobacco and/or cannabis smoking cessation using the chewing gum composition according to this invention are also provided.
    Type: Grant
    Filed: April 23, 2017
    Date of Patent: November 24, 2020
    Assignee: APIRx Pharmaceutical USA, LLC
    Inventors: Lekhram Changoer, George Anastassov
  • Ophthalmic composition
    Patent number: 10842787
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: November 24, 2020
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
  • Application of levorotatory tetrahydropalmatine to the treatment of depression disorders, bipolar and related disorders, and manic episodes
    Patent number: 10842788
    Abstract: The compound levorotatory-tetrahydropalmatine and pharmaceutical compositions thereof are provided for the treatment of ‘depressant disorders’, ‘bipolar and related disorders’, ‘manic episodes’ and ‘anxiety disorders’ as these disorders are defined in Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5).
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: November 24, 2020
    Assignee: PharmacoGenetics Limited
    Inventor: Hong Xue
  • Treatment of schizophrenia
    Patent number: 10842789
    Abstract: The present invention relates to a method of treating schizophrenia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a selective D3 antagonist, wherein said subject has at least one negative symptom (NS) among the following core negative symptoms in PANSS: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive withdrawal (N4), and Lack of Spontaneity (N6); with moderate or higher severity. Methods for improving the probability of success and/or the effect of a treatment of schizophrenia in a subject in need thereof are also described.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: November 24, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Françoise Tonner, Armida Mucci
  • Immunopotentiator potentiating tumor immunity or infection immunity
    Patent number: 10842790
    Abstract: An object of the present invention is to provide an immunopotentiating agent for reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity. Imatinib and/or a salt thereof has the action of reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity, and can be used as an active ingredient for the immunopotentiating agent.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: November 24, 2020
    Assignee: OSAKA UNIVERSITY
    Inventors: Hiroyoshi Nishikawa, Shimon Sakaguchi, Atsushi Tanaka
  • Small molecule inhibitors of EGFR and PI3K
    Patent number: 10842791
    Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazoline structure or a quinoline structure which function as dual inhibitors of EGFR proteins and PI3K proteins, and their use as therapeutics for the treatment of cancer and other diseases.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: November 24, 2020
    Assignee: The Regents of the University of Michigan
    Inventors: Christopher Emil Whitehead, Judith S. Leopold
  • Deuterated baricitinib
    Patent number: 10842792
    Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification, as well as pharmaceutical compositions comprising the same, and methods of using such compounds and compositions to inhibit at least one of Janus Kinase-1 and -2 and diseases associated with those kinases.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: November 24, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Inhibitors of the unconventional secretion of fibroblast growth factor 2 (FGF2) by tumor cells and uses thereof
    Patent number: 10842793
    Abstract: The present invention relates to compounds that have the capability of inhibiting the secretion of fibroblast growth factor 2 (FGF2) by tumor cells, as well as uses of said compound in medicine, in particular in the prevention and/or treatment of cancerous or inflammatory diseases.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: November 24, 2020
    Assignees: Universitat Heidelberg, European Molecular Biology Laboratory
    Inventors: Walter Nickel, Joe Lewis
  • Use of Sigma-1 receptor agonist compounds
    Patent number: 10842794
    Abstract: Compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. Embodiments relate to the use of Sigma-1 receptor agonists for use in the treatment of prevention of progressive fibrosis characterized by the over proliferation of ECM producing cells, e.g. myofibroblasts and by the excessive deposition of ECM components in a medical or disease condition. Preferred Sigma-1 agonists are disclosed.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: November 24, 2020
    Assignees: Támogatott Kutatócsoportok Irodája, Semmelweis Egyetem, SigmaDrugs Kft.
    Inventors: Andrea Fekete, Ádám Vannay, Endre Illés Kovács
  • Chemosensitization of resistant by synthetically related compounds
    Patent number: 10842795
    Abstract: Compounds for the chemosensitization of antibiotic resistant bacteria such as multidrug resistant (MDR) Pseudomonas aeruginosa (Pa) are provided. The compounds inhibit the MDR efflux proteins and re-sensitize the bacteria towards killing by antibiotics. Thus, the compounds are used in combination with antibiotics to treat or prevent infections caused by MDR bacteria.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: November 24, 2020
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Mahmoud A. Elfaky, Maan T. Khayat, Ghufran A. Alhowswi, Fatma M. Alhaity, Muna M. Albeeshy
  • Treatment of dementia
    Patent number: 10842796
    Abstract: The invention describes improved treatments for Frontotemporal dementia based on the use of a methylthioninium compound in combination with a compound which directly modifies synaptic neurotransmission in the brain, such as a symptomatic Alzheimer's disease treatment (e.g. acetylcholinesterase and/or memantine).
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: November 24, 2020
    Assignee: WisTa Laboratories Ltd.
    Inventors: Claude Michel Wischik, Björn Olaf Schelter, Damon Jude Wischik, John Mervyn David Storey
  • Nutraceutical co-crystal compositions
    Patent number: 10842797
    Abstract: Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: November 24, 2020
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Michael John Zaworotko, Heather Clarke, Arora Kapildev, Padmini Kavuru, Roland Douglas Shytle, Twarita Pujari, Lissette Marshall, Tien Teng Ong
  • Charged ion channel blockers and methods for use
    Patent number: 10842798
    Abstract: The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: November 24, 2020
    Assignee: Nocion Therapeutics, Inc.
    Inventors: Bridget McCarthy Cole, James Lamond Ellis
  • Serine/threonine kinase inhibitors
    Patent number: 10842799
    Abstract: Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: November 24, 2020
    Assignee: GENENTECH, INC.
    Inventors: Aleksandr Kolesnikov, Steven Do
  • Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
    Patent number: 10842800
    Abstract: Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor antagonist (GRA) and steroidogenesis inhibitors, and by concomitant administration of a GRA and CYP3A inhibitors. Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of mifepristone and ketoconazole. Subjects treated with CYP3A inhibitors or steroidogenesis inhibitors may suffer from toxicity or other serious adverse reactions; concomitant administration of other drugs would be expected to increase the risk of such toxicity and adverse reactions.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: November 24, 2020
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Joseph K. Belanoff
  • Optimizing mifepristone absorption
    Patent number: 10842801
    Abstract: The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration. Mifepristone absorption into the blood is increased upon administration with meals. The method of the invention can benefit patients suffering from conditions including psychiatric illnesses and hormonal disorders.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: November 24, 2020
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joe Belanoff, Robert Roe, Caroline Loewy
  • Controlled release pharmaceutical dosage forms
    Patent number: 10842802
    Abstract: The present disclosure provides novel controlled release pharmaceutical dosage form, methods of making the same, and methods of using the same to treat dermatological conditions.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: November 24, 2020
    Assignee: MEDICIS PHARMACEUTICAL CORPORATION
    Inventors: Sajeev Chandran, Shirishkumar Kulkarni, Pravin Meghrajji Bhutada, Ashish Ashokrao Deshmukh, Douglas Bakan, Mitchell Wortzman
  • Imidazopyridines Syk inhibitors
    Patent number: 10842803
    Abstract: Certain imidazopyridines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: November 24, 2020
    Assignee: KRONOS BIO, INC.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Scott A. Mitchell, Aaron C. Schmitt, Jianjun Xu, Zhongdong Zhao
  • Muparfostat for use in treating patients with hepatitis virus-related hepatocellular carcinoma after surgical resection
    Patent number: 10842804
    Abstract: Muparfostat for use in reducing intrahepatic tumor recurrence and increasing disease-free survival period in a hepatocellular carcinoma patient with microvascular invasion after curative liver resection, while excluding HCC patients with no vascular invasion and HCC patients with macrovascular invasion, is disclosed. The hepatocellular carcinoma patient with microvascular invasion is identified by examining a resected liver tumor sample from the HCC patient for the presence of microvascular invasion in the sample.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: November 24, 2020
    Assignee: Medigen Biotechnology Corporation
    Inventors: Stanley Chang, Kuan-Lang Lai
  • Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
    Patent number: 10842805
    Abstract: The invention relates to unique compositions containing enriched and purified natural crocin and/or crocetin for prevention and/or treatment of cancers and other conditions and diseases. Compositions comprise mainly enriched or purified natural crocin or crocetin or combination of both and possible other active phytochemicals. A composition is used as functional food, drink, dietary supplement, or therapeutic dosage to a human orally or through other appropriate way (parenteral, percutaneous, rectal, mucosal, intranasal or topical administration). A method of natural crocin and crocetin enriching and purification is revealed.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: November 24, 2020
    Inventor: Song Gao
  • Methods for treating ocular inflammatory disorders
    Patent number: 10842806
    Abstract: Provided are methods for treating ocular inflammatory disorders, including macular edema, using an AMP kinase activator, e.g., 5-aminoimidazole-4-carboxamide-1-?-d-ribofuranoside (AICAR). The method reduces inflammation, thereby minimizing the loss of vision or visual function associated with these ocular disorders.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: November 24, 2020
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Demetrios G. Vavvas, Joan W. Miller, Lucia Sobrin, Jun Suzuki
  • Methods of treating neurodegenerative disorders comprising DNA methyltransferase inhibitors
    Patent number: 10842807
    Abstract: The present disclosure provides a method of treating a neurodegenerative disorder, the method comprising administering a DNA methyltransferase inhibitor.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: November 24, 2020
    Assignee: Washington University
    Inventors: Hiroko Yano, Albert Kim
  • Polypeptide having the capacity to form alpha-1,3 glucosyl unit branchings on an acceptor
    Patent number: 10842808
    Abstract: Polypeptides having the ability to specifically form connections of glucosyl units in alpha 1,3 on an acceptor having at least one hydroxyl moiety are presented. The polypeptides include i) the pattern I of sequence SEQ ID NO: 1, ii) the pattern II of sequence SEQ ID NO: 2, iii) the pattern III of sequence SEQ ID NO: 3, and iv) the pattern IV of sequence SEQ ID NO: 4, or derivates from one or several of said patterns, wherein the polypeptide furthermore has an aspartic residue (D) at position 5 of the pattern II (SEQ ID NO: 2), a glutamic acid residue (E) at position 6 of the pattern III (SEQ ID NO: 3) and an aspartic acid residue (D) at position 6 of the pattern IV (SEQ ID NO: 4). Methods for producing acceptors connected to glucosyl units in alpha 1,3 using the polypeptides are also provided.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: November 24, 2020
    Assignees: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE TOULOUSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Magali Remaud-Simeon, Marlene Vuillemin, Claire Moulis, Pierre Monsan, Sandrine Morel
  • Pet food compositions
    Patent number: 10842809
    Abstract: Described herein are pet food compositions comprising a blood glucose management component comprising soy isoflavone and yeast beta-glucan (?-glucan); along with methods of making and using same.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 24, 2020
    Assignee: Hills Pet Nutrition, Inc.
    Inventors: Matthew Jackson, Dennis Jewell
  • Continuous release compositions made from hyaluronic acid, and therapeutic applications of same
    Patent number: 10842810
    Abstract: The present invention concerns polymer particles made from poly(lactic-co-glycolic acid) (PLGA) polymer, poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid) (PLGA-PEG-PLGA) copolymer, or the mixture of same, combined with hyaluronic acid molecules or hyaluronic acid salts, and the method for preparing same. The present invention also concerns injectable pharmaceutical or cosmetic compositions comprising such polymer particles, the method for preparing such compositions, and the use thereof for medical purposes, in particular for the prevention and/or treatment of musculoskeletal diseases, diseases and traumatic conditions of the skin, oral disorders, vaginal mucosa dryness and urinary infections or cystitis, dryness of the eye membrane and eye infections, obesity, and the use of same to combat ageing of the skin and/or for repairing the dermal tissue (mesotherapy).
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: November 24, 2020
    Assignee: GENBIOTECH
    Inventors: Yannis Guillemin, Dominique Vacher, Thomas Perrier, Maud Gonnet, Jean-Noël Gouze
  • Inulin for preventing antibiotic resistant infection and pathogen colonization
    Patent number: 10842811
    Abstract: The present disclosure provides for methods and compositions for the treatment and prevention of antibiotic-resistant infections or pathogen colonization in critically ill patients in the intensive care unit (ICU) or in other populations at high risk for such infections.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: November 24, 2020
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Julian Abrams, Daniel Freedberg
  • Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
    Patent number: 10842812
    Abstract: Methods of promoting hypoxia or the hypoxia response for the treatment or prevention of mitochondrial dysfunction and oxidative stress disorders are described. Methods for screening for targets of mitochondrial dysfunction and oxidative stress disorders are also described.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: November 24, 2020
    Assignees: The General Hospital Corporation, Massachusetts Institute of Technology
    Inventors: Vamsi K. Mootha, Isha Jain, Warren M. Zapol, Luca Zazzeron
  • Compositions of nitrates and methods of use thereof
    Patent number: 10842813
    Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 24, 2020
    Assignee: HEARTBEET LTD
    Inventors: Jon Lundberg, Eddie Weitzberg
  • Use of low dose arsenic for preserving genomic integrity
    Patent number: 10842814
    Abstract: Methods and compositions are provided for inhibiting, preventing, ameliorating and/or reducing damage to DNA in non-cancerous cells in a subject undergoing chemotherapeutic treatment and/or radiation treatment of cancer cells in the subject, comprising administering to the subject one or more compounds of arsenic in a therapeutically effective amount prior to chemotherapeutic treatment and/or radiation treatment.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: November 24, 2020
    Assignees: Board of Regents of the University of Texas System, Baylor College of Medicine
    Inventors: Chul Soo Ha, Zhi-Min Yuan, Hang Su, Edward Paul Hasty, Alison A. Bertuch, Maria Monica Gramatges, Gregory P. Swanson
  • Perispinal perfusion by administration of T regulatory cells alone or in combination with angiogenic cell therapies
    Patent number: 10842815
    Abstract: Disclosed are method of enhancing perispinal perfusion in a patient suffering from reduced perfusion of the lower back through administration of T regulatory cells alone capable of stimulating angiogenesis directly or through enhancement of angiogenic activities of cellular therapies. Said cellular therapies possessing angiogenic activities include mesenchymal stem cells, hematopoietic stem cells and endothelial progenitor cells. In one embodiment of the invention, administration of T regulatory cells is performed that are expanded ex vivo. For certain embodiment of the invention T regulatory cells may be autologous or allogeneic.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 24, 2020
    Inventors: Thomas Ichim, Amit Patel
  • Compositions and methods for isolating and enriching IgM-producing cells and uses thereof
    Patent number: 10842816
    Abstract: The technology described herein relates, at least in part, to compositions comprising and methods for isolating and enriching natural IgM-producing phagocytic B (NIMPAB) cells and methods of producing IgM antibodies using such cells, as well as uses of the antibodies produced by the methods for the prevention and treatment of diseases wherein immunotherapy with such natural IgM antibodies and their derivatives can be useful.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: November 24, 2020
    Assignees: Trustees of Boston University, Boston Medical Center Corporation
    Inventors: Xuemei Zhong, Joyce Wong
  • Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
    Patent number: 10842817
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: November 24, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Methods for preparing platelet products
    Patent number: 10842818
    Abstract: Provided herein are improved processes for preparing and treating platelet products. The methods are useful in the efficient preparation of platelet products with desirable characteristics, including pathogen inactivated platelet products.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: November 24, 2020
    Assignee: Cerus Corporation
    Inventor: Johannes Vermeij
  • Compositions and methods for treating itching, gingivostomatitis, and demodectic mange
    Patent number: 10842819
    Abstract: Provided are methods for treating itching caused by allergy, include itching associated with parasite-mediated inflammation (e.g., demodicosis, stomatitis, dermatophytosis, etc.), comprising administration to a mammalian subject in need thereof a therapeutically effective amount of a heat-treated, fractionated thymus extract composition (e.g., Thyex-1-6A and -6B compositions, comprising proteins or polypeptides having molecular weights in the range of 3.5 kDa to 30 kDa), in combination with or formulated with colostrum, to provide for reducing itching in the subject. Combination or adjunctive therapies comprising administration of a heat-treated, fractionated thymus extract composition in combination with or formulated with colostrum, and including at least one additional anti-parasitic, anti-bacterial, anti-fungal, anti-viral agent, or homeopathic agent are also provided.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: November 24, 2020
    Assignee: CMI Research Management, LLC
    Inventors: Ryan Ushijima, Richard N. Ushijima
  • Kits and methods for processing stem cells from bone marrow or umbilical cord blood
    Patent number: 10842820
    Abstract: Provided herein are kits for processing stem cells from bone marrow or umbilical cord blood, comprising: a) a precipitation reagent comprising an aqueous solution of 0.1-30% hydroxyethyl starch or 0.1-30% methyl cellulose, and 0.1-20% of cerebroprotein hydrolysate; and b) a separation reagent comprising an aqueous solution comprising Ficoll and diatrizoate and having a density of 1.0-1.2 g/ml, and methods of use. Further provided herein is a collection of stem cells obtained by the kits and methods disclosed herein comprising stem cells from bone marrow or umbilical cord blood, and uses thereof.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: November 24, 2020
    Assignee: Mingqi TANG
    Inventor: Mingqi Tang